Navigation Links
Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea

18, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders.

Research has shown that compounds can be created by chemically modifying certain tetracyclines and that these new compounds have properties that may make them effective in treating diseases involving inflammation and/or destruction of the body's connective tissues. CollaGenex is evaluating various chemically modified tetracyclines (so called "IMPACS" compounds because they are Inhibitors of Multiple Proteases And CytokineS") to assess whether they are safe and effective in these applications. The Company has a pipeline of innovative product candidates with possible applications in dermatology and other disease states. In addition, CollaGenex has acquired the SansRosa(TM) technology, which consists of a class of compounds that have shown promise in reducing the redness associated with rosacea, and the Restoraderm(R) technology, a unique, proprietary dermal drug delivery system. CollaGenex plans to leverage these platforms to develop a range of topical dermatological products with enhanced pharmacologic and cosmetic properties.

To receive additional information on the Company, please visit our Web site at www.collagenex.com, which does not form part of this press release.

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the Company's plans, timing and success related to its patent applications and the launch of Oracea for the treatment of inflammatory lesions of rosacea, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. CollaGenex' actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in the most recent Form 10-K for the yea
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting
6. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
7. King Pharmaceuticals Announces Plan to Report Positive Data from Phase III Clinical Trial Evaluating the Combination of Altace with Hydrochlorothiazide
8. Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
(Date:7/27/2015)... CTI BioPharma Corp. (NASDAQ and MTA: CTIC) ... quarter 2015 financial results on Thursday, August 6, 2015, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Thursday, August 6 1:30 ...
(Date:7/27/2015)... and PARIS , July ...  and Sanofi have entered into a new global ... treatments in the emerging field of immuno-oncology. As part ... a programmed cell death protein 1 (PD-1) inhibitor currently ... trials in 2016 with new therapeutic candidates based on ...
(Date:7/27/2015)... and WESTLAKE VILLAGE, Calif. ... AGN ) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: ... Commission (FTC) has granted early termination of the waiting ... (HSR Act) with respect to Allergan,s pending acquisition of ... On July 6, 2015, each of Allergan ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9
... (Nasdaq: VOLC ) today announced its intention to ... principal amount of convertible senior notes due September 1, 2015 ... as amended (the "Securities Act"). Prior to June 1, 2015, ... conversion, holders will receive up to the principal amount of ...
... Inc. (Nasdaq: ANDS ) announced today that it ... Friday, September 17, 2010 at 8:35 a.m. EDT (5:35 a.m. ... in Boston.  Steve Worland, Ph.D., President and Chief Executive Officer ... clinical development programs. Dr. Worland will also present ...
Cached Medicine Technology:Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 2Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 3Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 4Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 2
(Date:7/28/2015)... ... 2015 , ... American Sentinel University has been named an ... Geisinger Health System (GHS), one of the nation’s largest integrated health services organizations. ... access to American Sentinel’s affordable, flexible and CCNE-accredited RN to BSN nursing degree ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... Education courses throughout California in the fall of 2015 . These seventeen ... Occupational Therapists. , Optimizing Functional Mobility in the Older Adult , ...
(Date:7/28/2015)... ... 28, 2015 , ... Peter Forbes, President of the Veterans Fund of the United States, managing ... the Veterans Coalition, is spearheading a campaign to help homeless Veterans by giving them “A ... and trade skills. Forbes and the UVBH assists and supports Vets through the Veterans ...
(Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... Combination Product ... p.m. – 3:00 p.m. EDT, http:// http://www.fdanews.com/comboproductgmpcompliance , Manufacturing a ... makers of combination products things can get messy in a hurry. In a 46-page ...
(Date:7/27/2015)... ... ... The National Association of Professional Women (NAPW) honors Deana ... Circle. She is recognized with this prestigious distinction for leadership in healthcare. With more ... networking organization exclusively for professional women. , “I’m pleased to recognize Deana with this ...
Breaking Medicine News(10 mins):Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 2Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 4Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2
... Telik, Inc.,(Nasdaq: TELK ) announced positive results ... (ezatiostat HCl) Tablets in,myelodysplastic syndrome (MDS) that support ... were reported at the 49th annual meeting of ... objectives of the trial were to evaluate the ...
... Researchers may be able to develop an antidepressant which ... in the brain instead of taking a less direct ... to take effect, according to a new study presented ... The antidepressant is also thought to be effective in ...
... 4 key proteins could determine if more invasive treatment is necessary, ... be possible to use a blood test to detect lung cancer, ... , Publishing in the Dec. 10 issue of the ... for four blood proteins -- CEA, RBP, SCC and AAT -- ...
... Dec. 7 California,s,stem cell agency made the ... 10 applications for research grants because of apparent ... cell program, the,Foundation for Taxpayer and Consumer Rights ... organization added that,to completely resolve the matter, the ...
... (Nasdaq: HEII ),( http://www.heii.com ) announced today that ... stock from NASDAQ Capital Market and,withdrawing its common stock ... December 6, 2007 of its intent to withdraw its ... and,anticipates that the last day of trading on the ...
... Relief Survey are in, NEW YORK, Dec. 7 ... breakups anymore. The fast-paced world we live in has,given way ... young,women, face. This trend can be seen in girls all ... some of the factors that contribute,to this new wave of ...
Cached Medicine News:Health News:Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome 2Health News:Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome 3Health News:Study shows new strategy for developing antidepressants 2Health News:Study shows new strategy for developing antidepressants 3Health News:Blood Test to Detect Lung Cancer Being Eyed 2Health News:Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say 2Health News:Stem Cell Institute Correct in Rejecting Applications Over Conflicts of Interest; Institutions, Board Members Involved Must Be Identified, Consumer Advocates Say 3Health News:HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ 2Health News:HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ 3Health News:What Stresses Teens Out 2Health News:What Stresses Teens Out 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Cholesterol/HDL Standard 50 mg/dl....
Medicine Products: